Sec-2_Unit-4 Flashcards
TB intro
In 2023, 25L TB patients in Ind(27% of global tb cases)—India TB report 2024
TB treatment(Drugs,vaccine)
Rifampin, Ethambutol
BCG vaccine
Procurement challenge of DR-TB medications like
Delamanid
Bedaquiline
TB vaccine for adults
Spanish vaccine MTBVAC (Bharatbiotech conducting clinical trials of it in Ind)
TB conclusion(2)
SDG-3.3: End TB by 2030
World TB day 2024 theme:”Yes! We can end TB”
Malaria intro
In 2022, Ind accounted for 66% of malaria cases in WHO SE Asia region
Initiatives to tackle malaria(Ind(1), World(2))
National Malaria Control Prog
Global Malaria Prog(WHO)
E-2025
Malarial vaccines(2)
Mosquirix
R21/Matrix-M
2/5 plasmodium parasites pose most malaria threat
P. Falciparum
P. Vivax
Hepatitis intro
11.6% viral hepatitis disease burden(2nd after China)–Global Hepatitis Report 2024(WHO)
Hep-B,C most common(stat, cause which diseases)
- 1.3mn deaths due to viral hep in 2022. 83% by Hep-B, 17% by Hep-C(Global Hep Report 2024)
- Liver cirrhosis, Liver cancer
Non-viral Hep(2)
ALD
NAFLD
Cervical cancer intro
2nd most common cancer among women in Ind, 1.27L cases & 80k deaths annually(Lancet)
Lethal HPV types
HPV types 16 & 18->70% of all cervical cancer cases globally
Indigenous hpv vaccine
CERVAVAC
Cervical cancer WF
WHO 90-70-90 triple pillar intervention
NCD intro
Constitutes 63% of all deaths in India(WHO)
NCD initiative by WHO
NCD Implementation Roadmap 2023-30 for Global Action Plan
Govt prog for chronic diseases
NPCDCS(National Prog for Prevention & Control of Cancer, Diabetes, Cardiovascular diseases & Stroke)
AMR intro
Responsible for 5mn deaths in 2019(WHO)
AMR Initiatives(Ind(2),Global(1))
National Prog on AMR containment
AntiMicrobial Stewardship Prog(AMSP) by ICMR
Global Action Plan on AMR(WHO)
High prevalence of antibiotic drugs(data)
70% patients surveyed(NCDC survey)
